Isomorphic Labs raises $2.1B for AI-powered drug discovery, backed by Alphabet and sovereign wealth funds

Isomorphic Labs, the Alphabet-backed drug discovery company founded by DeepMind creator Demis Hassabis, has raised $2.1B in Series B funding. Thrive Capital led the round, with a roster of investors that reads like a who’s-who of deep-pocketed capital: Alphabet, GV, MGX, Temasek, CapitalG, and the U.K. government’s AI fund all participated.

What Isomorphic Labs actually does

The company is building what it calls IsoDDE, short for Isomorphic Drug Design Engine. Think of it as an AI system that can design drug molecules from scratch, predicting how they’ll interact with biological targets at the atomic level before anyone steps into a lab.

The technological backbone here is AlphaFold 3, the protein structure prediction model that earned Hassabis a Nobel Prize in Chemistry in 2024. AlphaFold cracked a problem that had stumped biologists for 50 years: predicting how proteins fold into three-dimensional shapes. Isomorphic takes that foundational capability and extends it into actual drug design.

The funding trail and what it signals

This $2.1B round follows a prior $600M external funding round. The plan is straightforward: use the money to refine the IsoDDE platform and push the company’s internal drug development pipeline toward clinical trials.

Hassabis has said the funding supports Isomorphic’s goal to build a scalable drug design engine capable of tackling all diseases.

Thrive Capital, the lead investor, is run by Josh Kushner. MGX is an Abu Dhabi-based technology investment fund, while Temasek is Singapore’s sovereign wealth fund. The participation of multiple Alphabet-affiliated entities, including Alphabet itself, GV (formerly Google Ventures), and CapitalG (Alphabet’s growth fund), underscores how deeply Google’s parent company is invested in this bet. Isomorphic was spun out of Alphabet in 2021 with Hassabis at the helm.

Why crypto and tech investors should pay attention

The risk profile is worth noting. Isomorphic has impressive technology but zero approved drugs. The gap between computational prediction and clinical reality has humbled plenty of AI biotech companies before. Protein structure prediction is solved. Designing drugs that actually work in human bodies, pass safety trials, and get regulatory approval is a different beast entirely.

The key metric to track isn’t the fundraise size. It’s whether Isomorphic’s pipeline actually enters clinical trials, and when. A $2.1B war chest buys significant runway, but the real validation comes from human data, not computational models.

Disclosure: This article was edited by Editorial Team. For more information on how we create and review content, see our Editorial Policy.